Jyong Biotech (NASDAQ:MENS) Reaches New 52-Week High - What's Next?

Key Points

• Jyong Biotech Ltd. (NASDAQ:MENS) reached a new 52-week high of $67.00, closing last at $65.62 with notable trading volume of 417,285 shares.
• Analysts from Wall Street Zen recently upgraded Jyong Biotech's rating to a "hold" as part of their comprehensive research on the company.
• The stock has experienced a significant 26.8% increase, with a fifty-day moving average recorded at $36.92.

Jyong Biotech Ltd. (NASDAQ:MENS - Get Free Report) shares hit a new 52-week high during mid-day trading on Friday . The stock traded as high as $67.00 and last traded at $65.62, with a volume of 417285 shares changing hands. The stock had previously closed at $51.75.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded shares of Jyong Biotech to a "hold" rating in a research report on Monday, June 30th.

Jyong Biotech Stock Down 9.3%

The stock has a fifty day simple moving average of $38.99.

Jyong Biotech Company Profile

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers' health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.